Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma
NCT ID: NCT06376617
Last Updated: 2024-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
60 participants
INTERVENTIONAL
2024-04-25
2025-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma
NCT00327197
Asthma Control in Elderly Patients With Montelukast
NCT01147510
Mold Sensitization Associated Severe Asthma Exacerbation
NCT03690349
Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients
NCT01246414
12-Week Study in Adult Subjects With Asthma
NCT01516073
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Severe asthma remains a challenge for patients and clinicians, as these patients are not only difficult to treat but also contribute disproportionately to the overall costs of asthma .
The reasons for the variation in severity of asthma from patient to patient are not fully understood. Several environmental factors, such as house dust mite, animal dander from pets, and environmental fungi (especially their continued exposure), are known to worsen asthma control (GINA ,2023).
Fungal diseases are a concern in the medical and public health community because of the increasing number of people with weakened immune systems and the advances in health care practices.
Fungi can be linked to severe asthma in a multitude of ways, including (inhalation of fungal spores; fungal sensitization,and allergic bronchopulmonary aspergillosis (ABPA) a severe degree of fungal sensitization culminating in irreversible bronchopulmonary damage Fungal infections are difficult to diagnose because clinical symptoms, signs, and radiographic manifestations are unspecific. Therefore, a definitive diagnosis requires direct identification of fungi from the site of infection.
Funal infection of air way can be diagnosed by :
* Microscopic Examination
* Culture of respiratory secretions (sputum,BAL), tissue samples, or blood.
* Serology : assay of serum that detect host antibodies reacting to fungal elements.
* Antigen antibodie :detection of components of the fungal wall that are shed into the bloodstream or other body fluids as the organism proliferates.
* PCR Up to 70% of severe asthmatics are IgE sensitized to fungi compared with 10% of mild-to-moderate asthmatics and 5% of the general population (RICK et al.,2020).
Exposure to outdoor fungal spores has been associated with worsening asthma symptoms, poor lung function, hospital admissions, and asthma- related death.(Agarwal et al.,2011).
Bronchoscopy is used as a diagnostic tool to observe endobronchial lesions and to obtain clinical specimens such as bronchoalveolar lavage (BAL) and bronchial washing. Fungal culture examination from clinical specimen of bronchoscopy could assist in diagnosing pulmonary mycosis (Hermansyah et al.,2021).
Bronchoalveolar lavage (BAL) is a common and relatively safe diagnostic procedure for the evaluation of patients with lung disease. It often provides valuable diagnostic information when clinical history, physical exam, routine laboratory testing, pulmonary function testing and radiographic imaging are insufficient to reach a definitive diagnosis. Compared to sputum analysis, BAL allows for targeted sampling of the lower respiratory tract with less microbial contamination from the upper aerodigestive tract (Davidson et al.,2020).
Aim of Work:
The aim of this study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma .
Study Design:
Prospective, cross sectional, observational study . study locality: All adult patients (\>18 years) with difficult to treat bronchial asthma or frequent exacerbation , admitted to or follow in outpatient clinic in Mansoura University chest department and Damietta chest hospital .
Sample Size :
(BAL) will collected from 60 patients with bronchial asthma
Patients and Methods:
Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication according to (GINA 2023).
Patients will classified according to Asthma Control Questionnaire (ACQ GINA2023 Asthma Control Questionnaire (ACQ):
In the past 4 weeks, has the patient had:
* Daytime asthma symptoms more than twice/week? Yes No
* Any night waking due to asthma? Yes No
* SABA\* reliever for symptoms more than twice/week? Yes No
* Any activity limitation due to asthma? Yes NO Well controlled: Non of these . Partly controlled: 1-2 Uncontrolled :3-4 Inclusion criteria
* Age 18 years or more.
* Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Exclusion criteria
1. Age less than 18 years.
2. Patients who do not give consent for the procedure.
3. Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
4. Pregnant women.
5. Patient already on antifungal treatment.
6. Bleeding profile abnormality.
7. patients during acute sever attacks .
All the patients will be subjected to the following:
1. Clinical evaluation:
\- Full history taking and clinical examination.
2. Laboratory work up:
* CBC
* Bleeding profile (INR)
3. ECG
4. pulmonary function test (pfts)with reversibility test Positive bronchodilator (BD) responsiveness (reversibility test) Is consider in adults if : increase in FEV1 of \>12% and \>200 mL (greater confidence if increase is \>15% and \>400 mL).
Measure change 10-15 minutes after 200-400 mcg salbutamol (albuterol) or equivalent, compared with pre-BD readings.
Before bronchodilator reversibility testing, short-acting and long-acting inhaled bronchodilators were withheld 4 and 12 hours; short-acting and long-acting oral bronchodilators were withheld 8 and 12 hours before testing, respectively Radiological work up
\- CT chest or chest x ray 6- Bronchoscopy with BAL: Bronchoscopy with BAL was performed according to standardized procedures designed to minimize oral contamination. BAL was performed by sequentially instilling and then withdrawing 50 ml aliquots of sterile normal saline.
Bronchoalveolar lavage fluid specimens collected under aseptic precautions was immediately transported to the laboratory for fungal processing BAL fluid should be collected in a labeled sterile container and transported expediently to the laboratory for analysis.
Microbiology work up :
BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.
Some pathogenic fungi grow slowly in culture and require plates to be held for up to 2 weeks, and in some case up to 4 weeks, before being discarded as negative. However, many common pathogenic fungi, such as Aspergillus fumigatus and Candida albicans, will produce identifiable colonies within 1-3days. Cultures should be examined at frequent intervals (at least three times weekly) .
Statistical analysis:
The collected data will be coded, processed and analyzed using SPSS program (Version 26) for windows. The appropriate statistical tests will be used when needed. P values less than 0.05 (5%) will be considered to be statically significant.
Ethical consideration:
* Study protocol will be submitted for approval by IRB
* Approval of the mangers of the health care facilities in which the study will be conducted
* Informed written consent will be obtained from each participant sharing in the study.
* Confidentiality and personal privacy will be respected in all levels of the study. Collected data will not be used for any other purpose
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study patern of fungal inection which cause excerbation
Take bal through fob and send for fungal stain and culure
fibroptic bronchoscopy
take bal through fibrooptic bronchoscopy and send for stain and culcure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fibroptic bronchoscopy
take bal through fibrooptic bronchoscopy and send for stain and culcure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with Uncontrolled bronchial asthma, frequent exacerbations and difficult to treat symptoms despite adherence to medication.
Exclusion Criteria
2. Patients who do not give consent for the procedure.
3. Patients with unstable cardiac conditions (recent myocardial infarction, cardiac arrhythmia, etc.)
4. Pregnant women.
5. Patient already on antifungal treatment.
6. Bleeding profile abnormality.
7. patients during acute sever attacks .
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tamer Awad
lecturer of chest medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS.24.03.2743
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.